1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional) is sponsored by National Institute on Aging (NIA). This funding opportunity through NIA's STTR program supports research that may lead to the development of innovative products and/or services for preventing and treating Alzheimer's disease and related dementias, or for caring for patients living with these conditions.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42) - Federal Grant Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42) The summary for the Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants. com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact .
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42): This Funding Opportunity Announcement (FOA) encourages applications to NIA's Small Business Technology Transfer Research (STTR)program to conduct research leading to the development of innovative products and/or services that may advance progress in preventing and treating Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD) and/or caring for and treating AD/ADRD patients.
Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42) National Institutes of Health (HHS-NIH11) Funding Opportunity Number: Current Application Deadline: Original Application Deadline: Maximum Federal Grant Award: Minimum Federal Grant Award: Expected Number of Awards: Cost Sharing or Matching: Applicants Eligible for this Grant Additional Information on Eligibility Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. Link to Full Grant Announcement http://grants.
nih. gov/grants/guide/pa-files/PAS-17-065. html Grant Announcement Contact If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster Similar Government Grants • Artificial Intelligence and Technology Collaboratory (P30 Clinical Trial Optional) • Artificial Intelligence and Technology Collaboratory Coordinating Center (U24 Clinical Tri...
• Claude D. Pepper Older Americans Independence Centers (P30 Clinical Trial Optional) • NIA Expanding Research in AD/ADRD (ERA) Summer Research Education Program (R25 Independent... • NIA Expanding Research in AD/ADRD (ERA) Postbaccalaureate Research Education Program (R25 ...
• Technological Enhancements and Archiving for Surveys of the Elderly: SBIR (R43/44) Initiat... • Technological Enhancements and Archiving for Surveys of the Elderly: STTR (R41/42) Initiat... • Technology and Aging: NIA Small Business Technology Transfer Program Initiative (STTR [R41...
More Grants from the National Institutes of Health • Kidney, Urologic, and Hematologic Diseases - Fostering the AdvanceMent of an Interactive L... • Transformative Non-Invasive/Minimally Invasive Technologies for Imaging the Olfactory Syst... • Single Source for Continuation of the Integrated Islet Distribution Program U24 (Clinical ...
• Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Bi... • Single Source: HeartShare 2. 0: Refining Heart Failure Subtypes and Treatment Targets for P...
Federal Grants by Category Grants for Single Mothers Small Business Grants for Women Federal Grants for College Federal Tuition Assistance
According to the current listing, eligibility includes: Small business concerns with a formal collaboration with a research institution. Confirm the full requirements in the official notice before applying.
Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional) is funded by National Institute on Aging (NIA). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The National Institute on Aging's FY 2026 AD/ADRD portfolio consolidates the dementia research infrastructure layer — NCRAD, NACC, the new AI and Technology Collaboratory Coordinating Center — into a small number of large, often single-source cooperative agreements. The $113M new-research increment goes elsewhere. For investigators submitting in FY 2026, the structural change matters more than the headline dollar number.
Read articleSeven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read article